FW-UC

FW-UC is a proprietary oral formulation of **niclosamide**, an FDA-approved small molecule historically used as an anthelmintic, now repurposed for its **anti-inflammatory and antiviral properties** in treating **ulcerative colitis (UC)**. Developed by **First Wave BioPharma**, it leverages niclosamide's ability to inhibit inflammatory pathways while minimizing systemic exposure due to low oral bioavailability, potentially offering a safer alternative to immunosuppressive therapies like corticosteroids for IBD patients. As part of the company's niclosamide portfolio, FW-UC targets gut-restricted activity to address unmet needs in moderate-to-severe UC.[1][7][11]